NUCLEUS 24 COCHLEAR IMPLANT SYSTEM
Cochlear Americas · Decision date Jun 25, 1998
What did the FDA approve?
FDA approved PMA P970051 for the Nucleus 24 Cochlear Implant System on June 25, 1998. The approval statement describes the device as intended to restore a level of auditory sensation to adults and children via electrical stimulation of the auditory nerve. The applicant was Cochlear Americas, and the device is classified under product code MCM as an implant, cochlear.
This record is an original PMA approval, not a supplement or manufacturing notice. The source does not include a supplement type or supplement reason. The statement reports the device's intended purpose only; it does not provide independent evidence of safety or clinical effectiveness, and no specific technical modifications, indications, or trial data are described in the supplied fields.
FDA approval order statement
INTENDED TO RESTORE A LEVEL OF AUDITORY SENSATIONTO ADULTS AND CHILDREN VIA ELECTRICAL STIMULATION OF THE AUDITORY NERVE.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Jun 25, 1998
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P970051
- Regulatory pathway
- Premarket approval application
- Applicant
- Cochlear Americas
- Product code
- MCM
- Decision code
- APPR
- Decision date
- Jun 25, 1998
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, cochlear.
- Applicant
- Cochlear Americas
- Product code
- MCM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P970051 received
Application receipt date recorded by FDA.
P970051 · FDA decision
APPR
P970051/S244 · Related supplement
Nucleus 24 Cochlear Implant System
Timeline entries are records held by MedtechLedger for P970051. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970051
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Nucleus 24 Cochlear Implant SystemP970051/S244 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Explore the linked device profile
Other records with product code MCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MED-EL Cochlear Implant SystemP000025/S136 | Med-El Corp. | PMA supplement | Oct 9, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP840024/S099 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP890027/S067 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
CLARION MULTI-STRATEGY COCHLEAR IMPLANTP960058/S178 | Advanced Bionics | PMA supplement | Sep 18, 2026 | FDA |
HiResolution Bionic Ear SystemP960058/S177 | Advanced Bionics | PMA supplement | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cochlear Americas
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10350 Park Meadows Dr., Lone Tree, CO, 80124
Sources and methodology
- Original FDA record: P970051
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


